Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872]
Corresponding Author of This Article
Qing Wang, PhD, Associate Professor, Department of Rehabilitation Center of Wuhan Puren Hospital, Wuhan University of Science and Technology, No. 1 Benxi Street, Qingshan District, Wuhan 430080, Hubei Province, China. qingpin6686@126.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2022; 10(22): 7872-7882 Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7872
Effect of celecoxib on improving depression: A systematic review and meta-analysis
Zhi Wang, Qiao Wu, Qing Wang
Zhi Wang, Integrated Traditional Chinese Medicine & Western Medicine Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Qiao Wu, Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Qing Wang, Department of Rehabilitation Center of Wuhan Puren Hospital, Wuhan University of Science and Technology, Wuhan 430080, Hubei Province, China
Author contributions: Wu Q and Wang Z contributed to database search, data extraction and data analysis; Wang Q contributed to paper writing and revision; All authors confirmed the final version of the manuscript.
Supported bythe Sixth Batch of Wuhan Young and Middle-aged Medical Backbone Talents Training Project Wuhan Health and Family Planning Commission, No. [2018] 116.
Conflict-of-interest statement: We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled.
PRISMA 2009 Checklist statement: We have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing Wang, PhD, Associate Professor, Department of Rehabilitation Center of Wuhan Puren Hospital, Wuhan University of Science and Technology, No. 1 Benxi Street, Qingshan District, Wuhan 430080, Hubei Province, China. qingpin6686@126.com
Received: February 27, 2022 Peer-review started: February 27, 2022 First decision: April 13, 2022 Revised: April 14, 2022 Accepted: June 24, 2022 Article in press: June 24, 2022 Published online: August 6, 2022 Processing time: 144 Days and 17 Hours
Abstract
BACKGROUND
Anti-inflammation drugs were uncovered to be a potential therapy for depression. Celecoxib as a selective COX2 inhibitor is also one anti-inflammation drugs. Celecoxib is widely used in the clinic, which is well known by medical workers. It is uncertain whether celecoxib has efficacy in improving depression.
AIM
To estimate the effect of celecoxib on improving depression.
METHODS
All literature was searched until 2022. The databases included PubMed, OVID database, Cochrane library, Web of Science, CNKI, Clinicaltrials.gov database and Wanfang database. The random effects model was used to estimate the standardized mean differences with 95%CIs. With determined diagnostic criteria, studies containing patients with depression in the celecoxib group and the control group were included in the meta-analysis. The primary outcome measures were set for depression scale scores.
RESULTS
Twenty-nine randomized controlled studies were included in the meta-analysis (including 847 subjects with depression and 810 control subjects). The meta-analysis showed that celecoxib had an effect of anti-depression. At the same time, heterogeneity was observed (I2 = 82.1%, P = 0.00), and meta-regression was implemented to estimate the source of heterogeneity, which showed that the type of depression scale and depression type may lead to the heterogeneity. Subgroup analysis with respect to depression scale and depression type suggested that depression type was the possible main source of heterogeneity. Moreover, Egger’s test, Begg’s test, funnel plot and Doi plot was implemented, and publication bias was found to be significant. Next, the trim and fill method was used to estimate the influence of publication bias on the outcome of the meta-analysis, which showed that the outcome of the meta-analysis was reliable. Sensitivity analysis was estimated by deleting a study one by one, and the outcome of the meta-analysis was significantly stable. The quality of all randomized controlled trial studies was assessed by risk of bias, which indicated the rank of evidence in the meta-analysis was high.
CONCLUSION
Celecoxib could be effective for improving depression.
Core Tip: There is inconsistency about the efficacy of celecoxib in improving depression. This is an updated systematic review and meta-analysis that includes more than 10 additional clinical trials compared to the previous meta-analysis. We compared the depression scale scores between the celecoxib group and the control group, and celecoxib had a significant reduction in depression scale scores and could be effective in improving depression.